Clisma Lax 133 ml 4 bottles rectal solution

Lax enema 133 ml 4 bottles rectal solution it's a evacuative enema based on sodium phosphate, indicated for treatment of occasional constipation and to promote rapid relief in case of constipation or intestinal irregularity. The package contains 4 single-dose bottles of 133 ml each, practical and ready to use, ideal for simple and hygienic application directly at the rectal level.

Thanks to his fast action, Clisma Lax acts locally by softening the stool and delicately stimulating evacuation, offering a immediate relief from the symptoms of constipation. The rectal solution is formulated with a combination of monobasic and dibasic sodium phosphate, which promotes an effective and safe laxative effect for the body. Clisma Lax is particularly suitable for those who need a rapid and targeted treatment of constipation, without having to resort to oral or prolonged therapies.

The practicality of single-dose enemas 133 ml allows immediate use without waste, making Clisma Lax the ideal solution for adults and adolescents looking for a laxative for rectal use reliable and easy to administer. Perfect for those who want to effectively and discreetly manage episodes of occasional constipation, Clisma Lax guarantees targeted action and a rapid return to intestinal well-being.

INDICATIONS

Why is Clisma Lax 133 ml 4 bottles rectal solution used? What is it for?

Short-term treatment of occasional constipation.

ACTIVE INGREDIENTS AND EXCIPIENTS

What is the composition of Clisma Lax 133 ml 4 bottles rectal solution?

Composition

100 ml contain 13.91 g of anhydrous monobasic sodium phosphate (NaH₂PO₄); 3.18 g of dibasic sodium phosphate (Na₂HPO₄). Excipients with known effects: sodium benzoate (100mg per 100ml) and methylparahydroxybenzoate (50mg per 100ml).

Excipients

Sodium hydroxide, sodium benzoate, methyl parahydroxybenzoate, purified water.

DOSAGE

How is Clisma Lax 133 ml 4 bottles rectal solution taken?

Dosage Adults and adolescents (12-18 years): the entire dose of the bottle. Method of administration Do not exceed the recommended doses. Laxatives should be used as infrequently as possible and for no longer than seven days. Use for longer periods of time requires a doctor's prescription after adequate evaluation of the individual case. Take preferably in the evening.

CONTRAINDICATIONS AND SIDE EFFECTS

When should Enema Lax 133 ml 4 bottles rectal solution not be used and what side effects can it cause?

Contraindications

-Hypersensitivity to the active ingredients or to any of the excipients (see the section "What is the composition of Clisma Lax 133 ml 4 bottles rectal solution?"). - acute abdominal pain or of unknown origin - nausea or vomiting - intestinal obstruction or stenosis or anorectal stenosis - intestinal sub-occlusion - mechanical ileus - paralytic ileus - inflammatory intestinal disorders and other conditions that can increase the absorption of the medicine - anal perforation - congenital or acquired megacolon - Hirschsprung's disease - rectal bleeding of unknown origin - acute haemorrhoidal crisis with pain and bleeding - severe state of dehydration - children under the age of twelve. Phosphates are contraindicated in patients with cardiac disorders, severe renal insufficiency or in the presence of hyperphosphatemia. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, must not be administered at the same time ((see the section "Which medicines or foods can modify the effect of Clisma Lax 133 ml 4 bottles rectal solution?")).

Side effects

Below are the side effects of sodium phosphate organized according to the MedDRA system organic classification. There is insufficient data to establish the frequency of the individual effects listed. Immune system disorders Hypersensitivity reactions (e.g. urticaria) Skin and subcutaneous tissue disorders Blisters, itching, burning Gastrointestinal disorders Isolated cramp-like pain or abdominal colic and diarrhea, with loss of fluids and electrolytes, more frequent in cases of severe constipation, as well as rectal irritation. Nausea, vomiting. Metabolism and nutrition disorders Hyperphosphatemia, hypokalemia, hypernatremia, hypocalcemia and tissue calcification may rarely occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

INTERACTIONS

Which medicines or foods can modify the effect of Clisma Lax 133 ml 4 bottles rectal solution?

The systemic absorption of sodium phosphate rectal solution is limited, however in some conditions it may be increased and predispose to possible interactions with other drugs. The simultaneous intake of drugs that can have effects on electrolyte balance (such as diuretics, cortisone, calcium channel blockers, lithium) can facilitate the onset of hyperphosphatemia, hypercalcemia and hypernatremia. Patients taking drugs that can prolong the QT interval may be at greater risk of developing this adverse reaction if treated concomitantly with sodium phosphate. Since hypernatremia is associated with low lithium levels, the concomitant use of Enema lax and lithium may cause a reduction in serum lithium levels, with a decrease in efficacy. Concomitant use of calcium supplements or calcium-containing antacids may increase the risk of ectopic calcification. Other preparations with sodium phosphates, including oral solutions or sodium phosphate tablets, must not be administered at the same time ((see the section "When should Enema Lax 133 ml 4 bottles rectal solution not be used and what side effects can it cause?")).

PREGNANCY AND BREASTFEEDING

Can Clisma Lax 133 ml 4 bottles rectal solution be used during pregnancy and breastfeeding?

There are no adequate and well-controlled studies on the use of the medicine during pregnancy or breastfeeding. Therefore the medicine must be used only if necessary, under the direct supervision of the doctor, after having evaluated the expected benefit for the mother in relation to the possible risk for the fetus or infant.

WARNINGS

What are the warnings of Clisma Lax 133 ml 4 bottles rectal solution?

Warnings and precautions

Pediatric population: The 133 ml bottle should not be used in children under 12 years of age. Abuse of laxatives (frequent or prolonged use or with excessive doses) can cause persistent diarrhea with consequent loss of water, mineral salts (especially potassium) and other essential nutritional factors. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Patients should be encouraged to drink fluids to help prevent dehydration, particularly patients with conditions that may predispose to dehydration, or those taking medications that may decrease the glomerular filtration rate, such as diuretics, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (sartans), or nonsteroidal anti-inflammatory drugs (NSAIDs). Since Clisma lax contains sodium phosphates, there is a risk of elevated serum sodium and phosphate levels and decreased calcium and potassium levels, and consequently hypernatraemia, hyperphosphataemia, hypocalcaemia and hypokalaemia, which may occur with clinical signs such as tetany and renal failure. Abuse of laxatives can cause dependence (and, therefore, possible need to progressively increase the dosage), chronic constipation and loss of normal intestinal functions (intestinal atony). Repeated use of laxatives can give rise to addiction or various types of damage. Prolonged use of a laxative to treat constipation is not recommended. The pharmacological treatment of constipation must be considered an adjuvant to the hygienic-dietary treatment (e.g. increase in vegetable fibers and liquids in the diet, physical activity and re-education of intestinal motility). The treatment of chronic or recurrent constipation always requires the intervention of a doctor for diagnosis, prescription of drugs and monitoring during the course of therapy. A careful evaluation by the doctor is essential when the need for the laxative derives from a sudden change in previous intestinal habits (frequency and characteristics of evacuations) that lasts for more than two weeks or when the use of the laxative fails to produce effects. Elderly people or those in poor health and patients with uncontrolled arterial hypertension, ascites, heart disease, changes in the rectal mucosa (ulcers, fissures) should consult their doctor before using the medicine. Patients should be advised to discontinue administration if resistance is encountered, as forcible administration of the enema may cause injury. In episodes of constipation, it is recommended first of all to correct eating habits by integrating the daily diet with an adequate intake of fiber and water. When using laxatives it is advisable to drink at least 6-8 glasses of water or other liquids a day to help soften the stool.

Overdose

The effect most frequently observed following ingestion or rectal administration is gastrointestinal irritation (abdominal pain, nausea, vomiting, diarrhoea). Persistent diarrhea results in loss of water, mineral salts (especially potassium) and other essential nutritional factors. Fluid and electrolyte losses must be replaced. Electrolyte imbalances are characterized by the following symptoms: thirst, vomiting, weakness, edema, bone pain (osteomalacia) and hypoalbuminemia. In more severe cases, the onset of dehydration or hypokalemia is possible which can cause cardiac or neuromuscular dysfunction, especially in the case of simultaneous treatment with cardiac glycosides, diuretics or corticosteroids. Fluid and electrolyte losses must be replaced. Generally, conservative measures are sufficient; plenty of liquids must be given, especially fruit juices. See also how much about the abuse of laxatives. If a significant amount of phosphate is absorbed, hyperphosphatemia, hypocalcemia, and hypomagnesemia may occur. Alterations in fluid and electrolyte balance have been observed following oral, rectal and intravenous exposure. Severe hyperphosphatemia and hypocalcemia may cause tetany, convulsions, bradycardia, QT interval prolongation, arrhythmia, coma and cardiac arrest. Severe dehydration, hypernatremia, hypotension, metabolic acidosis, and tachycardia may also occur. The elderly, children and patients with renal insufficiency are at increased risk of toxic effects.

Driving vehicles and using machinery

The medicine does not alter the ability to drive or use machines. However, it is possible that side effects may occur during treatment, therefore it is good to know the reaction to the drug before driving vehicles or using machinery.

CONSERVATION

How is Clisma Lax 133 ml 4 bottles rectal solution stored?

This medicinal product does not require any special storage conditions.

FORMAT

What is the format of Enema Lax 133 ml 4 bottles rectal solution?

DRUG LEGAL TEXT

Content responsibility

This sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.

Please note

The product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.

Data source: Farmadati Italia

Website: www.farmadati.it

The Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.

The Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO/IEC 27001:2017 for information security management systems.